GSFD yields 2760.91% · ABBV yields 3.06%● Live data
📍 GSFD pulled ahead of the other in Year 1
Combined, GSFD + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GSFD + ABBV for your $10,000?
Global Seafood Technologies, Inc. engages in the processing and packaging of shrimp for seafood restaurant chains and retail grocery outlets in the United States. The company operates through the Seafood, Fishing Bait, and Freshwater Shrimp segments. The Seafood segment performs processing, packaging, and storage of shrimp and other seafood products. The company provides frozen shrimp in various sizes and descriptions, which are packaged for commercial or consumer use. Frozen, headless shrimp with shell, is the principal product processed and packaged in one-pound and two-pound packages. Peeled shrimp is also processed under private labels for customers or for distribution to restaurants, and it is used in ready-to-cook meal kits for supermarket distribution. The Fishing Bait segment packages and distributes recreational fishing bait products. Its Killer Bee Bait products include varieties of bait shrimp, catfish bait, cut squid, whole squid, cigar minnows, ballyhoo, frozen chum, and menhaden oil. Killer Bee Bait products are sold through retail outlets and at independent marinas and bait shops. The Freshwater Shrimp segment engages in the development and harvesting of farm-grown and freshwater shrimp through its hatchery and nursery facility for sale to independent aquaculture farmers. Global Seafood Technologies is based in Biloxi, Mississippi.
Full GSFD Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.